Outcome of the Board meeting held on today 04th June, 2026.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 11.0 pts more than Nifty Microcap 250 and 11.0 pts more than its Healthcare Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Novelix Pharmaceuticals' board approved the issue and allotment of 12,00,000 equity shares to non-promoters on a preferential basis at Rs. 57 per share (face value Rs. 10 + premium of Rs. 47), aggregating to approximately Rs. 6.84 crore. The shares will be allotted to 13 named non-promoter allottees, subject to shareholder and regulatory approvals under Section 42 and 62 of the Companies Act, 2013 and SEBI ICDR Regulations. An Extra-Ordinary General Meeting (EGM) has been scheduled for July 1, 2026 via video conferencing to seek member approval, with a cut-off date of June 24, 2026 for e-voting eligibility. A Practicing Company Secretary has been appointed as scrutinizer for the e-voting process. The board meeting commenced at 5:00 PM and concluded at 9:15 PM on June 4, 2026.
This is a modest capital raise of about Rs. 6.84 crore through preferential allotment to non-promoter investors, which will dilute existing shareholders' stakes slightly. Bringing in multiple new non-promoter investors may be viewed positively as it broadens the shareholder base, though the small size of the raise limits any major impact on the stock.